


COMPARATIVE BIOSCIENCES, INC.

A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH



Xenograft Studies

Xenografts of human tumor tissue into laboratory animal species provide a more accurate model of tumor growth and activity of administered drugs than in vitro studies.

CBI offers in vivo xenograft services to conduct drug development for oncology, playing a major role in development of new anti-cancer medicines and therapies.

CBI has evaluated many potential anti-cancer compounds.

We offer the following benefits:

- Our expertise allows us to optimally design studies that provide critical preclinical efficacy data.
- We have several supporting capabilities including: clinical pathology, immunology, histopathology, immunohistochemistry.

We can help you advance your product by conducting the following evaluations in any of our xenograft models:

- Subcutaneous, intravenous and orthotopic implantation
- Immunocompromised and immunocompetent rodents, including knockout, transgenics and syngeneics
- Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
- Maximization of test article effectiveness and minimum effective dosage
- Combination therapy
- Comparison of formulation and routes of administration
- Maximum tolerated dose and pharmacokinetics/pharmacodynamics

For a list of the numerous validated cell lines for the assessment of anti-tumor agents, click the "Xenograft Studies" link below.

Leslie Nemeth at: 408-738-9263 • email: leslie_nemeth@compbio.com

Contact us for more information on Xenograft Studies.

CUCK HERE: Xenograft Studies CUCK HERE: Histological

Antibacterial Research & Consulting

CLICK HERE: